Connect Biopharma Holdings Ltd is a holding company mainly engaged in the development of clinical-stage biopharmaceutical therapies for the treatment of T cell-driven inflammatory diseases. Its product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha, or IL-4Ra, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis (AD), and asthma.